The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs purchased through the program. Under the proposed process, which also would be available to drug manufacturers, a decision-making body within the Department of Health and Human Services would review and resolve the claims. The proposed rule will be published in the Aug. 12 Federal Register with comments accepted through Oct. 11. AHA staff are reviewing the rule, and member hospitals that are 340B participants will receive more information.

Related News Articles

Headline
The Medicare Payment Advisory Commission March 15 released its March report to Congress, which includes its recent recommendations for hospital and other…
Blog
The Medicare Payment Advisory Commission (MedPAC) today released its annual March Report advising Congress on the Medicare fee-for-service (FFS) payment…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…
Headline
The House March 6 voted 339-85 to pass a package of six appropriations bills that would fund certain federal agencies through fiscal year 2024 and contains…
Headline
AHA Feb. 29 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B…